Expanded Access to Ziftomenib
Requests for single patient expanded access to ziftomenib monotherapy may be considered for eligible adult patients with Acute Lymphoblastic Leukemia (ALL) with KMT2A rearrangements, or Acute Myeloid Leukemia (AML), with NPM1 mutations or KMT2A rearrangements.

To request access, use Responsible Party contact information provided in this record.

Expanded access for ziftomenib is only available in the United States.
Acute Lymphoblastic Leukemia, With Appropriate Mutations|Acute Myeloid Leukemia, With NPM1 Mutations
DRUG: ziftomenib
â€¢ Subsection Condition:

* NPM1 mutation in AML patients
* KMT2A rearrangement in AML patients
* KMT2A rearrangement in ALL patients